ALSO NOTED: Kellogg wins big salary; Roche expects Ventana response; UK group invests in NanoBioDesign;and much more...

> It turns out that Peter Kellogg's defection from Biogen Idec to Merck was no lateral move for the CFO. He'll make $832,008 as a base salary for the drug giant, a hefty premium over the $568,387 he brought home for the big biotech. Add in bonuses and options and Kellogg actually earned $3.4 million in compensation last year. And he's on to some hefty extras at Merck as well. Report

> Roche says it expects a response to its Ventana bid by the middle of next week. Report

> Imperial Innovations Group say they have invested £500,000 in NanoBioDesign Limited, a company developing a range of toxicity screening systems to speed up the drug discovery process. Release

> With Brazilian officials playing tough, Abbott has cut the price of Kaletra for AIDS by nearly 30 percent. Report

> China's Fosun International, which has a big pharma division, will probably raise about $1.48 billion in its IPO. Report (WSJ sub. req.)

> The FDA is warning doctors against combining a Roche antibiotic with certain medications for babies. Report

And Finally… After all the talk, it turns out that men are just as chatty as women. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.